A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial.
about
Phase 1 study of pandemic H1 DNA vaccine in healthy adultsProspects for control of emerging infectious diseases with plasmid DNA vaccines.A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice.Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccineFDA guidance on prophylactic DNA vaccines: analysis and recommendations.Substitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibodyA 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunityA flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurateImmunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans.DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trialA West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial.Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trialA double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challengeCo-Administration of Molecular Adjuvants Expressing NF-Kappa B Subunit p65/RelA or Type-1 Transactivator T-bet Enhance Antigen Specific DNA Vaccine-Induced Immunity.Evaluation of candidate vaccine approaches for MERS-CoV.Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost.Middle East respiratory syndrome vaccines.Toward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015.Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery.Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.Comparative study of synonymous codon usage variations between the nucleocapsid and spike genes of coronavirus, and C-type lectin domain genes of human and mouse.Animal models in virus research: their utility and limitations.T cell-mediated immune response to respiratory coronaviruses.Antiparasitic DNA vaccines in 21st century.Recent Developments in Preclinical DNA Vaccination.Nucleic acid vaccination strategies against infectious diseases.Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice.Emerging viral diseases: confronting threats with new technologies.Comparison of JEV neutralization assay using pseudotyped JEV with the conventional plaque-reduction neutralization test.An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial.Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges.New approaches to vaccination
P2860
Q30373824-0A4D3801-935A-495C-A46B-E406F87ABDF4Q30380454-1D896E3B-CB4E-471E-B35E-F68F30AB1C88Q30398406-1B7D72D9-4DCC-4652-9C99-ED8D8D09CEBAQ30400066-FA344D7D-8598-46EE-ADE8-DC67C9F388E4Q30404941-0BBAC82A-BACD-416B-B2EF-E4EC68F2EBA6Q30430552-B4208F03-7C65-4B96-BCA7-940D82A16DBAQ33759465-8DF6ED6C-9F55-4A9F-AA26-6E3DE69BAB0BQ33897964-4C45546B-C04C-40F4-A9F6-5502F16D3EECQ33904997-8C62C267-63A6-416D-8A5E-3CC7FC055D70Q34242499-4FC3AA0D-8918-47C4-B60B-2783AB193242Q34247261-9F9F3843-0A06-467C-9D36-CCE767C6C845Q34263835-1787D19D-270A-4210-8A90-74D5FA239A66Q34407701-D45DAA56-CF04-48DF-87B6-64A8AC190915Q34663554-88D04861-93E5-4396-8AD9-34D6C22C3DF3Q34833926-3964C192-2212-47B6-8269-B6C475B30170Q35055198-83D6936E-52D4-4BE6-AF60-0EA54730EB7AQ35531454-7D6B83A8-E97E-49AE-92A7-0C34F9535F2BQ35826774-11187F03-5A71-4F9D-80E8-441EE108C806Q35917397-E4E177D1-3095-4BFF-B6BC-C3B856028B2BQ36573064-87F0889D-10F0-43D8-9644-41BDAE58B3E5Q37143501-E397810C-B3BB-440E-919F-1BD1273AF082Q37169882-37509A54-0936-4EA7-8753-611965D33CC7Q37351412-BD63D49D-E7FA-42C6-8BED-100DBD9B2738Q37366744-107C3AED-EBE7-4E3F-ACC2-F87BBC890D18Q37411209-B86D42B7-A0A2-4D87-837D-6C2F40589F40Q38043556-DAB8F6E3-DE53-49AE-8F9F-AF108D6BEFBCQ38213199-5E8DF1A0-5E13-4E38-81DA-5226A659F626Q38552711-459048F6-054B-4366-A923-0153CEB0EDB6Q38581976-FC637420-04A5-4EC4-92CA-6ED3696BF3D1Q38586079-95251535-0CEB-44F6-A0CE-3B71133E5CA6Q40744757-380714FC-CBA9-44CB-B6D6-244191E8A661Q41744062-978385CE-73F5-4E34-A6B1-A8BD3616F04CQ42232832-41493D9A-08E3-415C-B1DA-CA2A086803DAQ47105782-E3918164-ED32-43D5-8218-A74AA1AD6CE8Q47607374-E2F24F3E-5388-449F-897D-0818FA640C77Q57170110-F2B6EA56-FBB5-45FA-86FA-2F8F43B606E3
P2860
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A SARS DNA vaccine induces neu ...... s in a Phase I clinical trial.
@en
A SARS DNA vaccine induces neu ...... s in a Phase I clinical trial.
@nl
type
label
A SARS DNA vaccine induces neu ...... s in a Phase I clinical trial.
@en
A SARS DNA vaccine induces neu ...... s in a Phase I clinical trial.
@nl
altLabel
A SARS DNA vaccine induces neu ...... ts in a Phase I clinical trial
@en
prefLabel
A SARS DNA vaccine induces neu ...... s in a Phase I clinical trial.
@en
A SARS DNA vaccine induces neu ...... s in a Phase I clinical trial.
@nl
P2093
P2860
P50
P921
P1433
P1476
A SARS DNA vaccine induces neu ...... s in a Phase I clinical trial.
@en
P2093
Brenda D Larkin
Charla A Andrews
Ingelise J Gordon
Julie E Martin
LaSonji A Holman
Leatrice Vogel
Mario Roederer
Mark K Louder
Martha Nason
Mary E Enama
P2860
P304
P356
10.1016/J.VACCINE.2008.09.026
P407
P577
2008-09-26T00:00:00Z